Ms Liz-Anne Lewsley
- Affiliate -Clinical Trials Unit (School of Cancer Sciences)
email:
Liz-Anne.Lewsley@glasgow.ac.uk
Cancer Research UK Clinical Trials Unit, The Beatson West of Scotland Cancer Centre, 1053 Great Western Road, Glasgow, G12 0YN
Publications
2023
Smith, P. et al. (2023) The copy number and mutational landscape of recurrent ovarian high-grade serous carcinoma. Nature Communications, 14(1), 4387. (doi: 10.1038/s41467-023-39867-7) (PMID:37474499) (PMCID:PMC10359414)
Banerjee, S. et al. (2023) Efficacy and safety of weekly paclitaxel plus vistusertib vs paclitaxel alone in patients with platinum-resistant ovarian high-grade serous carcinoma: the OCTOPUS multicenter, phase 2, randomized clinical trial. JAMA Oncology, 9(5), pp. 675-682. (doi: 10.1001/jamaoncol.2022.7966) (PMID:36928279) (PMCID:PMC10020933)
Karamouza, E. et al. (2023) CA-125 early dynamics to predict overall survival in women with newly diagnosed advanced ovarian cancer based on meta-analysis data. Cancers, 15(6), 1823. (doi: 10.3390/cancers15061823) (PMID:36980708) (PMCID:PMC10047009)
2021
Hanna, C. R. et al. (2021) Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT). Radiation Oncology, 16, 163. (doi: 10.1186/s13014-021-01888-1) (PMID:34446053)
2020
Hanna, C. R. et al. (2020) Glasgow Early Treatment Arm Favirpiravir (GETAFIX) for adults with early stage COVID-19: A structured summary of a study protocol for a randomised controlled trial. Trials, 21(935), (doi: 10.1186/s13063-020-04891-1) (PMID:33213530) (PMCID:PMC7675389)
Talhouk, A. et al. (2020) Development and validation of the gene-expression predictor of high-grade-serous ovarian carcinoma molecular subTYPE (PrOTYPE). Clinical Cancer Research, 26(20), (doi: 10.1158/1078-0432.CCR-20-0103) (PMID:32554541) (PMCID:PMC7572656)
Millstein, J. et al. (2020) Prognostic gene expression signature for high-grade serous ovarian cancer. Annals of Oncology, 31(9), pp. 1240-1250. (doi: 10.1016/j.annonc.2020.05.019) (PMID:32473302) (PMCID:PMC7484370)
Paoletti, X. et al. (2020) Assessment of progression-free survival as a surrogate end point of overall survival in first-line treatment of ovarian cancer. JAMA Network Open, 3(1), e1918939. (doi: 10.1001/jamanetworkopen.2019.18939) (PMID:31922558) (PMCID:PMC6991254)
2018
Stronach, E. A. et al. (2018) Biomarker assessment of HR deficiency, tumor BRCA1/2 mutations and CCNE1 copy number in ovarian cancer: associations with clinical outcome following platinum monotherapy. Molecular Cancer Research, 16(7), pp. 1103-1111. (doi: 10.1158/1541-7786.MCR-18-0034) (PMID:29724815)
Fallon, M. T., Wilcock, A., Kelly, C. A. , Paul, J. , Lewsley, L.-A., Norrie, J. and Laird, B. J.A. (2018) Oral ketamine vs placebo in patients with cancer-related neuropathic pain: a randomized clinical trial. JAMA Oncology, 4(6), pp. 870-872. (doi: 10.1001/jamaoncol.2018.0131) (PMID:29621378) (PMCID:PMC6145686)
2017
Goranova, T. et al. (2017) Safety and utility of image-guided research biopsies in relapsed high-grade serous ovarian carcinoma—experience of the BriTROC consortium. British Journal of Cancer, 116, pp. 1294-1301. (doi: 10.1038/bjc.2017.86) (PMID:28359078) (PMCID:PMC5482731)
2014
Macpherson, I.R., Bray, C.A., Hopkins, C., Hannon, R.A., Lewsley, L.A., Ritchie, D.M. and Canney, P. (2014) Loading dose ibandronate versus standard oral ibandronate in patients with bone metastases from breast cancer. Clinical Breast Cancer, 15(2), pp. 117-127. (doi: 10.1016/j.clbc.2014.09.009) (PMID:25454689)
2013
Banerjee, S. et al. (2013) A multicenter, randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line chemotherapy for advanced ovarian cancer: an SGCTG (SCOTROC 4) and ANZGOG study on behalf of GCIG. Annals of Oncology, 24(3), pp. 679-687. (doi: 10.1093/annonc/mds494)
Articles
Smith, P. et al. (2023) The copy number and mutational landscape of recurrent ovarian high-grade serous carcinoma. Nature Communications, 14(1), 4387. (doi: 10.1038/s41467-023-39867-7) (PMID:37474499) (PMCID:PMC10359414)
Banerjee, S. et al. (2023) Efficacy and safety of weekly paclitaxel plus vistusertib vs paclitaxel alone in patients with platinum-resistant ovarian high-grade serous carcinoma: the OCTOPUS multicenter, phase 2, randomized clinical trial. JAMA Oncology, 9(5), pp. 675-682. (doi: 10.1001/jamaoncol.2022.7966) (PMID:36928279) (PMCID:PMC10020933)
Karamouza, E. et al. (2023) CA-125 early dynamics to predict overall survival in women with newly diagnosed advanced ovarian cancer based on meta-analysis data. Cancers, 15(6), 1823. (doi: 10.3390/cancers15061823) (PMID:36980708) (PMCID:PMC10047009)
Hanna, C. R. et al. (2021) Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT). Radiation Oncology, 16, 163. (doi: 10.1186/s13014-021-01888-1) (PMID:34446053)
Hanna, C. R. et al. (2020) Glasgow Early Treatment Arm Favirpiravir (GETAFIX) for adults with early stage COVID-19: A structured summary of a study protocol for a randomised controlled trial. Trials, 21(935), (doi: 10.1186/s13063-020-04891-1) (PMID:33213530) (PMCID:PMC7675389)
Talhouk, A. et al. (2020) Development and validation of the gene-expression predictor of high-grade-serous ovarian carcinoma molecular subTYPE (PrOTYPE). Clinical Cancer Research, 26(20), (doi: 10.1158/1078-0432.CCR-20-0103) (PMID:32554541) (PMCID:PMC7572656)
Millstein, J. et al. (2020) Prognostic gene expression signature for high-grade serous ovarian cancer. Annals of Oncology, 31(9), pp. 1240-1250. (doi: 10.1016/j.annonc.2020.05.019) (PMID:32473302) (PMCID:PMC7484370)
Paoletti, X. et al. (2020) Assessment of progression-free survival as a surrogate end point of overall survival in first-line treatment of ovarian cancer. JAMA Network Open, 3(1), e1918939. (doi: 10.1001/jamanetworkopen.2019.18939) (PMID:31922558) (PMCID:PMC6991254)
Stronach, E. A. et al. (2018) Biomarker assessment of HR deficiency, tumor BRCA1/2 mutations and CCNE1 copy number in ovarian cancer: associations with clinical outcome following platinum monotherapy. Molecular Cancer Research, 16(7), pp. 1103-1111. (doi: 10.1158/1541-7786.MCR-18-0034) (PMID:29724815)
Fallon, M. T., Wilcock, A., Kelly, C. A. , Paul, J. , Lewsley, L.-A., Norrie, J. and Laird, B. J.A. (2018) Oral ketamine vs placebo in patients with cancer-related neuropathic pain: a randomized clinical trial. JAMA Oncology, 4(6), pp. 870-872. (doi: 10.1001/jamaoncol.2018.0131) (PMID:29621378) (PMCID:PMC6145686)
Goranova, T. et al. (2017) Safety and utility of image-guided research biopsies in relapsed high-grade serous ovarian carcinoma—experience of the BriTROC consortium. British Journal of Cancer, 116, pp. 1294-1301. (doi: 10.1038/bjc.2017.86) (PMID:28359078) (PMCID:PMC5482731)
Macpherson, I.R., Bray, C.A., Hopkins, C., Hannon, R.A., Lewsley, L.A., Ritchie, D.M. and Canney, P. (2014) Loading dose ibandronate versus standard oral ibandronate in patients with bone metastases from breast cancer. Clinical Breast Cancer, 15(2), pp. 117-127. (doi: 10.1016/j.clbc.2014.09.009) (PMID:25454689)
Banerjee, S. et al. (2013) A multicenter, randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line chemotherapy for advanced ovarian cancer: an SGCTG (SCOTROC 4) and ANZGOG study on behalf of GCIG. Annals of Oncology, 24(3), pp. 679-687. (doi: 10.1093/annonc/mds494)